Novartis’ shift toward high-innovation pharmaceuticals has made regulatory milestones, late-stage trial results, and new product rollouts top priorities for investors. Progress on key therapies such as remibrutinib, Fabhalta, and ianalumab will likely influence the company’s long-term growth trajectory far more than minor quarterly earnings fluctuations.
Industry analysts also view several experimental medicines as critical to the next phase of growth. Pelacarsen in cardiovascular disease, remibrutinib in multiple sclerosis, and Del-desiran in genetic disorders are widely seen as important long-term opportunities. Collectively, these therapies are estimated to have peak annual sales potential exceeding $10 billion, which would help offset expected revenue losses when blockbuster medicines such as Cosentyx and Kisqali face patent expirations around the turn of the decade.
Investors will also focus on management’s commentary regarding the second half of 2026. The company previously guided for stronger growth later in the year as comparisons become easier after the initial wave of generic competition. Any indication that this recovery remains on track would likely reassure investors that 2026 represents a transition year rather than the beginning of a longer slowdown.
Finally, analysts will pay close attention to research and development spending. Novartis has deliberately continued investing aggressively despite lower earnings. If management maintains this strategy while preserving margins, it would reinforce confidence that today’s spending is intended to support tomorrow’s product launches rather than simply offset current weaknesses.
Why U.S. Drug Pricing Reforms Could Become an Even Bigger Risk Than Quarterly Earnings
Although second-quarter numbers will attract most of the immediate attention, a much larger issue has been dominating discussions across the global pharmaceutical industry in recent months: the impact of the Most Favored Nation (MFN) pricing policy.
President Donald Trump’s MFN pricing policy has fundamentally changed how pharmaceutical companies think about launching medicines around the world. Under the policy, prices paid in the United States — the world’s most profitable pharmaceutical market — can increasingly be linked to prices charged in other wealthy countries, including many European nations.
For decades, drugmakers accepted lower prices across Europe because premium pricing in the United States largely compensated for thinner overseas margins. That model is now under pressure. Novartis CEO Vas Narasimhan recently warned that the full impact of the policy could become visible over the next 18 months, describing it as a potentially “very difficult situation” for both patients and pharmaceutical companies.
If a medicine launches first in Europe at relatively low prices, those prices could eventually influence what companies are allowed to charge in the United States. Because the U.S. market generates significantly higher profits, pharmaceutical companies may increasingly delay European launches in order to protect American pricing.
This is the critical link between European access to medicines and U.S. pricing policy. Lower prices negotiated by European health systems can indirectly reduce the profitability of launching a medicine in the United States. As a result, companies may choose to prioritize the U.S. market first and delay launching new therapies in Europe.
Narasimhan has warned that unless European governments improve how they reward medical innovation, patients across Europe could face slower access to breakthrough treatments. Novartis currently expects only a modest direct financial impact, estimating that MFN presently affects roughly 5% to 10% of Medicaid-related sales.
However, industry leaders believe the longer-term strategic implications are considerably larger. Novartis is far from alone: executives at Roche and AstraZeneca have also warned that Europe’s fragmented reimbursement systems, slower regulatory processes, and lower medicine prices risk making the region increasingly unattractive for launching innovative therapies.
Recent industry data already suggest that this shift may be beginning. According to GlobalData, new medicine launches in Europe have fallen by roughly one-third since the MFN policy was introduced, as companies increasingly seek to protect pricing in the United States.